DalCor is developing precision treatments for cardiovascular disease by genetically targeting patients that will derive clinical benefits
DalCor Pharmaceuticals has raised $80.0M in total funding. The most recent round was Series D. The last funding was announced in September 2023.
DalCor Pharmaceuticals's investors include Caisse de Depot et Placement du Quebec, Fonds de solidarite FTQ, Andes, Investissement Quebec, CTI Life Sciences Fund.
DalCor Pharmaceuticals is headquartered in Montreal, Canada.
DalCor is developing precision treatments for cardiovascular disease by genetically targeting patients that will derive clinical benefits
DalCor Pharmaceuticals is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"DalCor Pharmaceuticals — Funding & Investors." VCBacked, September 13, 2023, https://www.vcbacked.co/company/dalcor-pharmaceuticals. Accessed July 31, 2026.
VCBacked. (2023). DalCor Pharmaceuticals — Funding & Investors. Retrieved July 31, 2026, from https://www.vcbacked.co/company/dalcor-pharmaceuticals
{{cite web |title=DalCor Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/dalcor-pharmaceuticals |website=VCBacked |access-date=July 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated